Rapid Diagnostic Service

The King’s Health Partners Rapid Diagnostic Service (RDS) Biobank was established in 2021. This biobank serves as a valuable resource for future research into patients who meet the criteria for the rapid diagnostic service, particularly those experiencing vague but concerning symptoms.

​

The RDS pathway is designed for patients with non-specific symptoms, enabling early detection of cancer or other serious conditions. Along with blood samples, the biobank stores relevant pathological data, as well as patient demographics, clinical information, and follow-up data.

​

Since its inception in 2016, the Rapid Diagnostic Service at Guy’s and St Thomas’s NHS Trust has seen over 3,500 patients, with approximately 8% receiving a diagnosis of cancer.

​

In addition, the RDS-Bio Study is an ongoing clinical trial that seeks to evaluate the predictive value of biomarkers in enhancing the RDS diagnostic capabilities. The study aims to identify high-risk patients who may benefit from earlier intervention or more intensive investigation.

​

Applications to access the biobank’s samples or data are accepted from investigators in both academic and commercial sectors.